Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Merck
since
auto-detected in 30 stories
22 days ago
23 days ago
Merck nears deal for flu-prevention biotech Cidara
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
37 days ago
Eli Lilly and Merck’s blockbuster drug sales power earnings ⊕⊕
found
a story from Financial Times ✅ › Financial Times
Pharma groups boost financial outlooks as revenues from flagship medicines like Zepbound and Keytruda leap
Stocks making the biggest moves premarket: Alphabet, Microsoft, Meta Platforms, Eli Lilly, Merck & more
These are some of the stocks posting the largest moves in early trading.
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit ⊕
Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs."
39 days ago
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings ⊕
found
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
80 days ago
Senior UK official asks whether pause in pharma sector spending is ‘co-ordinated’
found
a story from Financial Times ✅ › Financial Times
Eli Lilly, Merck and AstraZeneca have all said in recent weeks that they plan to roll back investment
84 days ago
US urged UK to offer a better deal on drug pricing to pharma companies
found
a story from Financial Times ✅ › Financial Times
Ambassador’s meeting with chancellor Rachel Reeves came days before AstraZeneca and Merck paused projects in Britain
86 days ago
Merck's pneumococcal shot shows promise in children and teens in study
Merck's pneumococcal vaccine showed strong immune responses in children and teens at higher risk of serious illness in a late-stage study, the drugmaker said.
Big pharma will stop investing in UK, warns eminent scientist Sir John Bell
found
a story from The Guardian ⚠️ › International
Warning follows news of US drugmaker Merck’s decision to scrap planned £1bn London research centre
Sir John Bell, a prominent scientist who brought business and government together during the Covid-19…